Journal of General Internal Medicine

, Volume 9, Issue 6, pp 339–348

Recent advances in the acute management of migraine and cluster headaches

  • Kusum L Kumar
Clinical Review


I have discussed the pharmacokinetics, efficacies, and side effects of the various nonnarcotic drugs available for the treatment of patients who have headache. Sumatriptan, the newest one, is expensive but may be cost-effective for those who have failed traditional migraine treatment, who visit the ER frequently, who have potential for drug abuse, or who have to miss time from school or work due to the headache. Studies are in progress to compare sumatriptan with other available drugs such as DHE-45 and to determine its possible role in the prophylaxis of migraine. A new 5-HTID receptor agonist with more efficacy and fewer side effects may be developed in the future. When sumatriptan and DHE-45 are contraindicated due to hypertension or coronary artery disease, other drugs such as metoclopramide, ketorolac, and butorphanol can be used as alternatives.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992;267:64–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Osterhaus JT, Autterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the United States. Pharmaco Economics. 1992;2:67–76.Google Scholar
  3. 3.
    Mathew NT. Transformed migraine. Cephalalgia. 1993;13(suppl 12):78–83.PubMedGoogle Scholar
  4. 4.
    Schulman EA, Silberstein SD. Symptomatic and prophylactic treatment of migraine and tension-type headache. Neurology. 1992;42(suppl 2):16–21.PubMedGoogle Scholar
  5. 5.
    Caekebeke JFV, Ferrari MD, Zwetsloot CP, Jansen J, Saxena PR. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology. 1992;42:1522–6.PubMedGoogle Scholar
  6. 6.
    Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291–4.PubMedGoogle Scholar
  8. 8.
    The sumatriptan Auto-injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323–31.Google Scholar
  9. 9.
    Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothcrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Fowler PA, Lacey LF, Keene ON, Thomas M. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia. 1991;11:228–9.CrossRefGoogle Scholar
  11. 11.
    Scott AK, Walley T, Breckenridge AM, Lacey LF, Fowler PA. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol. 1991;32:581–4.PubMedGoogle Scholar
  12. 12.
    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, Cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):19–36.Google Scholar
  13. 13.
    The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316–21.CrossRefGoogle Scholar
  14. 14.
    Ensink FBM. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol. 1991;238:566–9.CrossRefGoogle Scholar
  15. 15.
    Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. U.S. Sumatriptan Research Group. Arch Neurol. 1992;49:1271–6.PubMedGoogle Scholar
  16. 16.
    The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:332–8.Google Scholar
  17. 17.
    Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol. 1991;238:562–5.CrossRefGoogle Scholar
  19. 19.
    The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol. 1991;31:314–22.Google Scholar
  20. 20.
    The Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol. 1992;32:177–84.Google Scholar
  21. 21.
    The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med. 1991;325:322–6.CrossRefGoogle Scholar
  22. 22.
    Ekbom K, Monstad I, Prusinsi A, Cole JA, Pilgrim AJ, Noronha D. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand. 1993;88:63–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol. 1991;31:339–44.PubMedGoogle Scholar
  24. 24.
    Willett F, Curzen N, Adams J, Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ. 1992;304:1415.PubMedGoogle Scholar
  25. 25.
    Curtin T, Brook AP, Roberts J. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305:713–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Inman W, Kubota K. Cardiorespiratory distress after sumatriptan given by injection. BMJ. 1992;305:714.PubMedGoogle Scholar
  27. 27.
    Lloyd DK, Pilgrim AJ. The safety of sumatriptan in asthmatic migraineurs. Cephalalgia 1993;13:201–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Ottervanger JP, Paalman HJA, Boxma GL, Strieker BH. Transmural myocardial infarction with sumatriptan. Lancet. 1993;341:861–2.PubMedCrossRefGoogle Scholar
  29. 29.
    McCarthy BG, Peroutka SJ. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR43175). Headache. 1989;29:420–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.PubMedGoogle Scholar
  31. 31.
    Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168–71.CrossRefGoogle Scholar
  32. 32.
    Belgrade MJ, Ling LJ, Schleevogt MB, Ettinger MG, Ruiz E. Comparison of a single dose meperidine, butorphanol, and dihydroer-gotamine in the treatment of vascular headache. Neurology. 1989;39:590–2.PubMedGoogle Scholar
  33. 33.
    Bell R, Montoya D, Shnaib A, Lee AM. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med. 1990;19:1079–82.PubMedCrossRefGoogle Scholar
  34. 34.
    Saadah HA. Abortive headache therapy with intramuscular dihydroergotamine. Headache. 1992;32:18–20.PubMedCrossRefGoogle Scholar
  35. 35.
    Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992;32:21–3.PubMedCrossRefGoogle Scholar
  36. 36.
    Bousser MG, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia. 1985;5(suppl 3):554–5.Google Scholar
  37. 37.
    DiSerio F, Patin J, Friedman A. USA trials of dihydroergotamine nasal spray in the acute treatment of migraine headache. Cephalalgia. 1989;9(suppl 10):344–5.Google Scholar
  38. 38.
    Krause KH, Bleicher MA. Dihydroergotamine nasal spray in the treatment of migraine attacks. Cephalalgia. 1985;5(suppl 3):138–9.Google Scholar
  39. 39.
    Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7(suppl 6):440–1.Google Scholar
  40. 40.
    Paiva T, Esperanca P, Marcelino L, Assis G. A double-blind trial with dihydroergotamine spray in migraine crisis. Cephalalgia. 1985;5(suppl 3):140–1.Google Scholar
  41. 41.
    Rohr J, Dufresne JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(suppl 3):142–3.Google Scholar
  42. 42.
    Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks: a double-blind crossover study with placebo. Cephalalgia. 1987;7:131–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Mondell B, DiSerio F, Friedman A. Dihydroergotamine nasal spray in the acute treatment of migraine headache [abstract]. Clin Pharmacol Ther. 1989;45:161.Google Scholar
  44. 44.
    Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine. Ann Emerg Med. 1993;22:191–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Pages LJ, Martinez JJ, Garg DC, et al. Pharmacokinetics of ketorolac tromethamine in hepatically impaired US young healthy subjects [abstract]. J Clin Pharmacol. 1983;27:324.Google Scholar
  47. 47.
    Stansk DR, Cherry C, Bradley R, Sarnquist FH, Yee JP. Efficacy and safety of single doses of intramuscular ketorolac tromethamine compared with meperidine for post-operative pain. Pharmacotherapy. 1990;10:405–45.Google Scholar
  48. 48.
    Brown CR, Moodie JE, Evans SA, et al. Efficacy of intramuscular ketorolac and meperidine in pain following major oral surgery [abstract]. Clin Pharmacol Ther. 1988;43:161.CrossRefGoogle Scholar
  49. 49.
    Spindler JS, Mehlisch D, Brown CR. Intramuscular ketorolac and morphine in the treatment of moderate to severe pain after major surgery. Pharmacotherapy. 1990;10:515–85.Google Scholar
  50. 50.
    Harden RN, Carter TD, Gillman CS, Gross AJ, Peters JR. Ketorolac in acute headache management. Headache. 1991;31:463–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache. 1991;31:523–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Turkewitz LJ, Sadaly JS, Dawson GA, et al. Self-administration of parenteral ketorolac tromethamine for head pain. Headache. 1992;32:452–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Larkin GL, Prescott JE. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine. Ann Emerg Med. 1992;21:919–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Duarte C, Dunaway F, Turner L, Aldag J, Frederick R. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: a randomized, prospective, double-blind trial. Ann Emerg Med. 1992;21:1116–21.PubMedCrossRefGoogle Scholar
  55. 55.
    Koffer H, Hildebrand J III, Connell M. Potential for non-narcotic analgesics to save personnel costs associated with controlling injectable morphine and meperidine. Am J Hosp Pharm. 1990;47:1084–8.PubMedGoogle Scholar
  56. 56.
    Elenbaas RM, Iacono CU, Koellner KJ, et al. Dose effectiveness and safety of butorphanol in acute migraine headache. Pharmacotherapy. 1991;11:56–63.PubMedGoogle Scholar
  57. 57.
    Diamond S, Freitag FG, Diamond ML, Urban G. Transnasal butorphanol in the treatment of migraine headache pain. Headache Q. 1992;3:164–71.Google Scholar
  58. 58.
    Sicuteri F, Fusco BM, Marabini S, et al. Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain. 1989;5:49–53.PubMedCrossRefGoogle Scholar
  59. 59.
    Fusco BM, Geppetti P, Fanciullacci M, Sicuteri F. Local application of capsaicin for the treatment of cluster headache and idiopathic trigeminal neuralgia. Cephalalgia. 1991;11(suppl 11):234–5.Google Scholar
  60. 60.
    Marks DR, Rappaport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia. 1993;13:114–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Sicuteri F, Raino I, Geppetti P. Substance P and endogenous opioid: how and where they could play a role in cluster headache. Cephalalgia. 1983;3(suppl 1):143–5.PubMedGoogle Scholar
  62. 62.
    Geppetti P, Fusco BM, Marabini S, et al. Secretion, pain and sneezing induced by the application of capsaicin to the nasal mucosa in man. Br J Pharmacol. 1988;93:509–14.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1994

Authors and Affiliations

  • Kusum L Kumar
    • 1
    • 2
  1. 1.Headache ClinicVeterans Affairs Medical CenterUSA
  2. 2.Oregon Health Sciences UniversityPortland

Personalised recommendations